𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Accuracy of International Guidelines for Identifying Significant Fibrosis in Hepatitis B e Antigen–Negative Patients With Chronic Hepatitis

✍ Scribed by Sanai, Faisal M.; Babatin, Mohammed A.; Bzeizi, Khalid I.; AlSohaibani, Fahad; Al–Hamoudi, Waleed; Alsaad, Khaled O.; Al Mana, Hadeel; Handoo, Fayaz A.; Al–Ashgar, Hamad; AlGhamdi, Hamdan; Ibrahim, Abeer; Aljumah, Abdulrahman; Alalwan, Abduljaleel; AlTraif, Ibrahim H.; Al–Hussaini, Hussa; Myers, Robert P.; Abdo, Ayman A.

Book ID
122370507
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
754 KB
Volume
11
Category
Article
ISSN
1542-3565

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60